We also demonstrate that tamoxifen, a typical anti-estrogen drug that is administered as first-line treatment for advanced breast cancer patients and for the prevention of breast cancer, selectively down regulates Elovl2, which implies that endogenous DHA production may be significantly affected in patients undergoing endocrine therapy. The gene discussed is ELOVL2; the disease is breast cancer.